Vivos Therapeutics Enters Securities Purchase Agreement

TL;DR

Vivos Therapeutics just signed a deal to sell more stock, raising cash.

AI Summary

On September 18, 2024, Vivos Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with certain investors. The company also announced unregistered sales of equity securities, details of which are provided in the filing. The filing also includes other events and financial statements/exhibits.

Why It Matters

This filing indicates Vivos Therapeutics is raising capital through a securities purchase agreement, which could impact its financial position and future operations.

Risk Assessment

Risk Level: medium — Entering into a securities purchase agreement and unregistered sales of equity securities can dilute existing shareholders and signal potential financial needs.

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• September 18, 2024 (date) — Date of earliest event reported
• Securities Purchase Agreement (agreement) — Material Definitive Agreement

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar
• $3.15 — ("Common Stock") at a purchase price of $3.15 per Share. No common stock purchase war
• $3.9375 — n the Offering) at an exercise price of $3.9375 per share of Common Stock, exercisable
• $4.3 m — fering are expected to be approximately $4.3 million, before deducting the Placement A

Filing Documents

• form8-k.htm (8-K) — 52KB
• ex5-1.htm (EX-5.1) — 13KB
• ex10-1.htm (EX-10.1) — 259KB
• form10-2.htm (EX-10.2) — 113KB
• ex99-1.htm (EX-99.1) — 16KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-037254.txt ( ) — 722KB
• vvos-20240920.xsd (EX-101.SCH) — 3KB
• vvos-20240920_lab.xml (EX-101.LAB) — 33KB
• vvos-20240920_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities The information contained above in Item 1.01 related to the issuance of the Placement Agent Warrants is hereby incorporated by reference into this Item 3.02. The Placement Agent Warrants and the shares of Common Stock issuable upon exercise of the Placement Agent have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and are instead being offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act. Item8.01. Other Events. On September 19, 2024, the Company issued a press release (the "Press Release") announcing the pricing of the Offering. A copy of the Press Release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K, the Press Release and statements of the Company's management made in connection therewith contain "forward-looking of 1934, as amended) concerning future events, including statements related to the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the intended use of proceeds from the Offering. Words such as "may", "should", "expects", "projects," "intends", "plans", "believes", "anticipates", "hopes", "estimates", "goal" and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Company's control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could

View Full Filing

View this 8-K filing on SEC EDGAR